Please assess the completion status of the following clinical trial:

Trial Title: VRS-317 in Adult Subjects With Growth Hormone Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 25 to 65 years~2. Negative serum pregnancy test for females of childbearing potential~3. Documented confirmation (medical history) of GHD during adulthood by one or more GH stimulation test~4. If taking hormone replacement therapy other than rhGH, patient must be on a stable course of treatment for 2 months prior to enrollment~5. Pituitary disorder associated with GHD has been clinically stable for at least 6 months~6. Currently receiving daily recombinant human growth hormone (rhGH) injections for treatment of GHD for a minimum of 28 days~7. Willing and able to give informed consent~8. Within one year from enrollment, normal result from screening including: mammogram (women), pap smear (women over 25), Men over 50 years old: digital rectal exam~Exclusion Criteria:~1. Subjects who have received systemic treatment for any bacterial, viral or fungal infection within 30 days of the first study drug dosing (prophylactic acyclovir for HSV is permitted)~2. Subjects with documented history of diabetes mellitus or inadequate glucose control as defined by fasting plasma glucose level of greater than 126 mg/dL (7 mM) or HbA1c of ≥ 6.5% at screening~3. Subjects with untreated adrenal insufficiency.~4. Free thyroxine below normal reference range or TSH above normal reference range~5. Current use of oral or inhaled steroids except for physiological maintenance doses of oral glucocorticoids in patients with multiple pituitary hormone deficiencies~6. Women using oral estrogens, including birth control pills, during study (transdermal estrogen patches are allowed)~7. Current significant cardiovascular, cerebrovascular, pulmonary, neurological (not related to GHD), renal or hepatobillary disease~8. Presence of retinopathy or papillaedema~9. Documented history of persistent (unresolved without medical intervention) or recurring migraines, edema, arthralgia (not related to osteoarthritis), or nausea~10. History of drug or alcohol abuse.~11. Must not have documented prior history of HIV, HBV or HCV infection(testing not required)~12. Prior history of cancer excluding adequately treated non-melanoma skin cancers or adequately treated in situ carcinoma of the cervix~13. Women who are pregnant or breastfeeding~14. Unwilling to use two effective birth control methods until Day 60 of Treatment Phase~15. Pre-existing antibodies to human growth hormone at time of screening (screening samples must be below pre-specified cut-off for positive anti-hGH antibody titer)~16. Treatment with an investigational drug within past 30 days prior to screening~17. Unable to comply with requirements of this study.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VRS-317 Safety Arm 1 (Type: EXPERIMENTAL): VRS-317 Single injection SC of dose level 1 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume
- VRS-317 Safety Arm 2 (Type: EXPERIMENTAL): VRS-317 Single injection SC of dose level 2 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume
- VRS-317 Safety Arm 3 (Type: EXPERIMENTAL): VRS-317 Single injection SC of dose level 3 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume
- VRS-317 Safety Arm 4 (Type: EXPERIMENTAL): VRS-317 Two injections SC of dose level 4 (based on 90 kg patient)~Placebo Two SC injection Dose matched to treatment volume
- VRS-317 Safety Arm 5 (Type: EXPERIMENTAL): VRS-317 Two injections SC of dose level 5 (based on 90 kg patient)~Placebo Two SC injections Dose Volume matched to active treatment volume

Based on this trial design, predict the completion outcome and termination type (if applicable).